|
Sunday — November 15, 2015
|
TOP STORIES |
|
A novel glaucoma monitoring system is being developed to guide providers in establishing personalized monitoring schedules that would help them avoid missing significant progression in glaucoma suspects or patients with open-angle glaucoma, said Joshua D. Stein, MD, MS. » Find out more |
|
Although research has led to improvements in understanding the pathophysiology of adenoviral conjunctivitis and in its diagnosis, there remains a need for further advances, said Anat Galor, MD. » What is lacking |
|
Analyses of data from the OASIS study confirm the efficacy of intravitreal ocriplasmin for the treatment of symptomatic vitreomacular traction/vitreomacular adhesion (VMT/VMA) and the importance of proper patient selection, said Peter K. Kaiser, MD. » Read about the data |
|
A phase III gene therapy trial for Leber congenital amaurosis showed that patients’ mean mobility test scores promptly improved after treatment, and the benefit was sustained at 1 year, said Albert M. Maguire, MD. » What the results mean |
FROM THE SHOW FLOOR |
|
Alphaeon Corp. announced it has entered into a definitive agreement with PhysIOL SA, of Belgium, to jointly develop and commercialize an exclusive Alphaeon-branded trifocal lens technology. » Read about the deal |
|
Two new non-mydriatic cameras from Carl Zeiss Meditec use a high-resolution optical chain, delivering enhanced retinal details for more effective detection and management of eye diseases. » Learn more |
|
|
We welcome your feedback!
Please send your comments to:
Mark L. Dlugoss
Group Content Director
UBM Medica Eyecare Group
mark.dlugoss@ubm.com |
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times.
The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA.
For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|
